These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9873451)

  • 21. The de novo design and synthesis of cyclic urea inhibitors of factor Xa: initial SAR studies.
    Galemmo RA; Maduskuie TP; Dominguez C; Rossi KA; Knabb RM; Wexler RR; Stouten PF
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2705-10. PubMed ID: 9873607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of glycolic and mandelic acid derivatives as factor Xa inhibitors.
    Su T; Wu Y; Doughan B; Kane-Maguire K; Marlowe CK; Kanter JP; Woolfrey J; Huang B; Wong P; Sinha U; Park G; Malinowski J; Hollenbach S; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2279-82. PubMed ID: 11527714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amido-(propyl and allyl)-hydroxybenzamidines: development of achiral inhibitors of factor Xa.
    Gong Y; Pauls HW; Spada AP; Czekaj M; Liang G; Chu V; Colussi DJ; Brown KD; Gao J
    Bioorg Med Chem Lett; 2000 Feb; 10(3):217-21. PubMed ID: 10698439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and discovery of 1-(2-(6-Chloro-3-methylsulfonyl)-naphthyl)-1H-pyrazole-5-carboxylamides as highly potent factor Xa inhibitors.
    Jia ZJ; Scarborough RM; Zhang P; Halfon S; Arfsten AE; Sinha U; Zhu BY
    Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):1004-7. PubMed ID: 19721266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors.
    Yoshikawa K; Yoshino T; Yokomizo Y; Uoto K; Naito H; Kawakami K; Mochizuki A; Nagata T; Suzuki M; Kanno H; Takemura M; Ohta T
    Bioorg Med Chem Lett; 2011 Apr; 21(7):2133-40. PubMed ID: 21345673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1H-pyrrolo[2,3-b]pyridine: A new scaffold for human neutrophil elastase (HNE) inhibitors.
    Crocetti L; Giovannoni MP; Schepetkin IA; Quinn MT; Khlebnikov AI; Cantini N; Guerrini G; Iacovone A; Teodori E; Vergelli C
    Bioorg Med Chem; 2018 Nov; 26(21):5583-5595. PubMed ID: 30385225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and synthesis of factor Xa inhibitors and their prodrugs.
    Song Y; Clizbe L; Bhakta C; Teng W; Wong P; Huang B; Tran K; Sinha U; Park G; Reed A; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2003 Jan; 13(2):297-300. PubMed ID: 12482444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.
    Ishihara T; Seki N; Hirayama F; Orita M; Koshio H; Taniuchi Y; Sakai-Moritani Y; Iwatsuki Y; Kaku S; Kawasaki T; Matsumoto Y; Tsukamoto S
    Bioorg Med Chem; 2007 Jun; 15(12):4175-92. PubMed ID: 17416533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-activity relationships of potent and selective factor Xa inhibitors: benzimidazole derivatives with the side chain oriented to the prime site of factor Xa.
    Ueno H; Katoh S; Yokota K; Hoshi J; Hayashi M; Uchida I; Aisaka K; Hase Y; Cho H
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4281-6. PubMed ID: 15261287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, and structure-activity relationships of unsubstituted piperazinone-based transition state factor Xa inhibitors.
    Huang W; Naughton MA; Yang H; Su T; Dam S; Wong PW; Arfsten A; Edwards S; Sinha U; Hollenbach S; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2003 Feb; 13(4):723-8. PubMed ID: 12639567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.
    Pinto DJ; Orwat MJ; Wang S; Fevig JM; Quan ML; Amparo E; Cacciola J; Rossi KA; Alexander RS; Smallwood AM; Luettgen JM; Liang L; Aungst BJ; Wright MR; Knabb RM; Wong PC; Wexler RR; Lam PY
    J Med Chem; 2001 Feb; 44(4):566-78. PubMed ID: 11170646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel, potent and selective chimeric FXa inhibitors featuring hydrophobic P1-ketoamide moieties.
    Semple JE; Levy OE; Minami NK; Owens TD; Siev DV
    Bioorg Med Chem Lett; 2000 Oct; 10(20):2305-9. PubMed ID: 11055344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aminoisoquinolines: design and synthesis of an orally active benzamidine isostere for the inhibition of factor XA.
    Choi-Sledeski YM; Becker MR; Green DM; Davis R; Ewing WR; Mason HJ; Ly C; Spada A; Liang G; Cheney D; Barton J; Chu V; Brown K; Colussi D; Bentley R; Leadley R; Dunwiddie C; Pauls HW
    Bioorg Med Chem Lett; 1999 Sep; 9(17):2539-44. PubMed ID: 10498204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isoxazolines and isoxazoles as factor Xa inhibitors.
    Pruitt JR; Pinto DJ; Estrella MJ; Bostrom LL; Knabb RM; Wong PC; Wright MR; Wexler RR
    Bioorg Med Chem Lett; 2000 Apr; 10(8):685-9. PubMed ID: 10782664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonbenzamidine tetrazole derivatives as factor Xa inhibitors.
    Quan ML; Ellis CD; He MY; Liauw AY; Woerner FJ; Alexander RS; Knabb RM; Lam PY; Luettgen JM; Wong PC; Wright MR; Wexler RR
    Bioorg Med Chem Lett; 2003 Feb; 13(3):369-73. PubMed ID: 12565931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 7-fluoroindazoles as potent and selective inhibitors of factor Xa.
    Lee YK; Parks DJ; Lu T; Thieu TV; Markotan T; Pan W; McComsey DF; Milkiewicz KL; Crysler CS; Ninan N; Abad MC; Giardino EC; Maryanoff BE; Damiano BP; Player MR
    J Med Chem; 2008 Jan; 51(2):282-97. PubMed ID: 18159923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.
    Sutton JC; Bolton SA; Davis ME; Hartl KS; Jacobson B; Mathur A; Ogletree ML; Slusarchyk WA; Zahler R; Seiler SM; Bisacchi GS
    Bioorg Med Chem Lett; 2004 May; 14(9):2233-9. PubMed ID: 15081015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.
    Shi Y; Li C; O'Connor SP; Zhang J; Shi M; Bisaha SN; Wang Y; Sitkoff D; Pudzianowski AT; Huang C; Klei HE; Kish K; Yanchunas J; Liu EC; Hartl KS; Seiler SM; Steinbacher TE; Schumacher WA; Atwal KS; Stein PD
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6882-9. PubMed ID: 19896847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological activity of non-amidine factor Xa inhibitors containing pyridine N-oxide and 2-carbamoylthiazole units.
    Haginoya N; Kobayashi S; Komoriya S; Yoshino T; Nagata T; Hirokawa Y; Nagahara T
    Bioorg Med Chem; 2004 Nov; 12(21):5579-86. PubMed ID: 15465335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guanylpiperidine peptidomimetics: potent and selective bis-cation inhibitors of factor Xa.
    Tamura SY; Levy OE; Uong TH; Reiner JE; Goldman EA; Ho JZ; Cohen CR; Bergum PW; Nutt RF; Brunck TK; Semple JE
    Bioorg Med Chem Lett; 2000 Apr; 10(8):745-9. PubMed ID: 10782677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.